Liquidia Corporation (NASDAQ:LQDA – Get Free Report) shares passed above its 50-day moving average during trading on Tuesday following a better than expected earnings announcement. The stock has a 50-day moving average of $49.65 and traded as high as $51.69. Liquidia shares last traded at $51.40, with a volume of 2,846,811 shares.
The company reported ($2.64) earnings per share for the quarter, missing the consensus estimate of $0.96 by ($3.60). The firm had revenue of $225.30 million for the quarter, compared to the consensus estimate of $214.18 million. Liquidia had a negative net margin of 15.15% and a positive return on equity of 184.00%. The company’s revenue for the quarter was up 314.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.04) earnings per share.
Latest Liquidia News
Investors following LQDA have been watching these news items:
- Positive Sentiment: Third-quarter revenue reached $225.3 million, up 314.9% year over year and ahead of expectations, with YUTREPIA sales of $222.7 million. The earnings coverage highlights strong product demand; a large charge obscured the reported loss, while adjusted results beat estimates. LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales
- Positive Sentiment: Management reported record October shipments and expanding PAH adoption, suggesting demand continued after the quarter. The post-settlement market outlook may also help Liquidia pursue growth, although referral disruptions remain a consideration. LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook
- Neutral Sentiment: Commercial growth is encouraging, but the company noted referral disruptions amid market changes, which could affect the pace of adoption. Earnings call outlook
Analyst Upgrades and Downgrades
Read Our Latest Research Report on LQDA
Insider Buying and Selling
In related news, insider Jason Adair sold 688 shares of the firm’s stock in a transaction that occurred on Monday, October 26th. The stock was sold at an average price of $43.19, for a total transaction of $29,714.72. Following the completion of the transaction, the insider owned 177,269 shares of the company’s stock, valued at $7,656,248.11. This trade represents a 0.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Rajeev Saggar sold 9,218 shares of the firm’s stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $28.48, for a total value of $262,528.64. Following the transaction, the insider directly owned 126,368 shares of the company’s stock, valued at approximately $3,598,960.64. This trade represents a 6.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 566,579 shares of company stock worth $25,746,120 over the last three months. Corporate insiders own 25.60% of the company’s stock.
Institutional Investors Weigh In On Liquidia
A number of institutional investors have recently modified their holdings of the stock. Pinnacle Wealth Planning Services Inc. raised its position in shares of Liquidia by 26.2% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 1,557 shares of the company’s stock worth $47,000 after purchasing an additional 323 shares during the last quarter. Sterling Capital Management LLC boosted its stake in Liquidia by 839.1% in the 3rd quarter. Sterling Capital Management LLC now owns 2,329 shares of the company’s stock worth $70,000 after purchasing an additional 2,081 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in Liquidia by 13.8% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,634 shares of the company’s stock worth $80,000 after purchasing an additional 320 shares in the last quarter. Globeflex Capital L P purchased a new stake in Liquidia during the 2nd quarter valued at about $175,000. Finally, Nykredit A S purchased a new stake in Liquidia during the 2nd quarter valued at about $177,000. 64.54% of the stock is owned by hedge funds and other institutional investors.
Liquidia Stock Performance
The firm has a market capitalization of $4.94 billion, a P/E ratio of 23.26, a price-to-earnings-growth ratio of 0.45 and a beta of 0.40. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. The business’s 50 day simple moving average is $49.42 and its two-hundred day simple moving average is $54.60.
About Liquidia
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing treatments for pulmonary hypertension and other serious diseases. Its work includes inhaled therapies designed to deliver medicines to the lungs. The company’s marketed product, Yutrepia (treprostinil) inhalation powder, is approved in the United States for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Liquidia also has a pipeline of investigational therapies, including other formulations of treprostinil.
See Also
- Five stocks we like better than Liquidia
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
